Respiratory Medicine

Pulmonary response to glucagon-like peptide-1 receptor agonist therapy in adults with cystic fibrosis-related diabetes: factors associated with improvement in FEV₁

By Sasan Mirfakhraee, Marconi Abreu, Akruti Singh, Jessica D. Abramowitz

Graphical abstract from Respiratory Medicine — Graphical abstract. Mirfakhraee et al.

Cohort study of 23 peopleInterventions

6 months, declared ties to: Cystic Fibrosis Foundation, Vertex Pharmaceuticals, 4D Molecular Therapeutics and 3 more

The paper

Sasan Mirfakhraee, Marconi Abreu, Akruti Singh, Jessica D. Abramowitz

The University of Texas Southwestern Medical Center

Respiratory Medicine, 2 Sep 2026

doi.org/10.1016/j.rmed.2026.109137 PubMed 42685881

Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs